Loading clinical trials...

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

A Phase IIIB, Open-label, Randomized, Multi-center Study Evaluating the Effect on Serum Lipids Following a Switch to ATV/r in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPV/r Based Regimen.

NCT00120393•Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

Patients with HIV who are virologically suppressed on a lopinavir/ritonavir combination highly active antiretroviral therapy (HAART) regimen but with elevated non-HDL cholesterol are randomized to remain on lopinavir/ritonavir or change to atazanavir/ritonavir in combination with current nucleoside reverse transcriptase inhibitors (NRTIs).

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•HIV positive
•LPV/RTV-based HAART for at least 6 months
•HIV-1 RNA less than 50c/mL (confirmed)
•Non-HDL higher than 160 mg/dL
•CD4 of at least 50 cells/mL

Exclusion Criteria

•Use of lipid-lowering agents

Locations (14)

Local Institution

Phoenix, Arizona, United States

Local Institution

Bakersfield, California, United States

Local Institution

Los Angeles, California, United States

Local Institution

San Francisco, California, United States

Local Institution

Miami, Florida, United States

Local Institution

Boston, Massachusetts, United States

Local Institution

New York, New York, United States

Local Institution

Cincinnati, Ohio, United States

Local Institution

Portland, Oregon, United States

Local Institution

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

January 1, 2004

Primary Completion Date

May 1, 2006

Completion Date

May 1, 2006

Last Updated

February 5, 2010

Enrollment

192

ESTIMATED participants

Conditions

HIV Infections

Interventions

atazanavir/ritonavir +2 NRTIs (immediate Switch Group)

DRUG

LPV/r +2 NRTIs (Delayed/optional Switch Group)

DRUG

Skeletal Muscle Energetics and Fatiguability in Older Individuals

NCT04142047

HIVHIV Infections

View study

RECRUITINGPHASE3

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805

HIV Infections

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2010Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of HIV Patients With Undetectable Viral Load and Abnormal Lipids Switching to Atazanavir/Ritonavir

Inclusion Criteria

Exclusion Criteria

Skeletal Muscle Energetics and Fatiguability in Older Individuals

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Clinic vs Clinic+Community Outreach HPV Self-Collection to Increase Cervical Screening in Women With HIV

Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR)

Comprehensive HIV and Harm Prevention Via Telehealth

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706